Public, NASDAQ:SCRX
NASDAQ Global Select Market
Sciele Pharma signs contract with Addrenex
Date: Tue, 01 Jul 2008 17:39:00 GMT
Tags:
Sciele Pharma signs contract with Addrenex
Forbes - Jul 1, 2008
Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications - Trading Markets (press release)
Pharmaceutical Business Review
Forbes - Jul 1, 2008
AP 07.01 . 08 , 1 : 12 PM ETSpecialty pharmaceutical company Sciele Pharma Inc . said Tuesday it signed a deal for marketing rights to Addrenex Pharmaceuticals Inc . ' s drug compound ADX415 ...
Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension - Business Wire (press release)Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications - Trading Markets (press release)
Pharmaceutical Business Review
Sciele and Novo Nordisk granted approval for diabetes drug
Date: Wed, 25 Jun 2008 10:32:06 GMT
Tags:
Sciele and Novo Nordisk granted approval for diabetes drug
Pharmaceutical Business Review - Jun 25, 2008
Pharmaceutical Business Review - Jun 25, 2008
Under a previously announced agreement , Sciele Pharma will exclusively market PrandiMet to physicians in the US.Sciele Pharma anticipates that PrandiMet will be available to physicians and patients ...
FDA approves Sciele's PrandiMet
Date: Tue, 24 Jun 2008 14:37:50 GMT
Tags:
FDA approves Sciele's PrandiMet
Triangle Business Journal - Jun 24, 2008
Triangle Business Journal - Jun 24, 2008
The US Food and Drug Administration has approved the use of PrandiMet , a combination tablet of repaglinide and metformin used to treat type 2 diabetes and that is marketed by an Atlanta drug ...
Market Report -- In Play (SCRX)
Date: Tue, 24 Jun 2008 14:37:28 GMT
Tags:
Market Report -- In Play (SCRX)
MSN Money - Jun 24, 2008
MSN Money - Jun 24, 2008
Sciele Pharmaand Novo Nordisk annonce the FDA Approves PrandiMet , a replaglinide and metformin fixed - dose combination tablet for treatment of type 2 diabetes The co and Novo Nordisk ( NVO ...
Sciele Pharma says FDA Approves PrandiMet tablets - Quick Facts
Date: Tue, 24 Jun 2008 14:09:33 GMT
Tags:
Sciele Pharma says FDA Approves PrandiMet tablets - Quick Facts
RTT News - Jun 24, 2008
RTT News - Jun 24, 2008
( RTTNews ) - Sciele Pharma ( SCRX : News , Chart , Quote ) on Tuesday said that the US Food and Drug Administration approved PrandiMet or repaglinide and metformin HCl tablets , a fixed - dose ...
SCIELE PHARMA, INC. Files SEC form 8-K, Other Events (EDGAR Online)
Date: Tue, 1 Jul 2008 18:34:11 Etc/GMT
Tags:
Sciele Pharma signs contract with Addrenex (AP)
Date: Tue, 1 Jul 2008 17:12:10 Etc/GMT
Tags:
Specialty pharmaceutical company Sciele Pharma Inc. said Tuesday it signed a deal for marketing rights to Addrenex Pharmaceuticals Inc.'s drug compound ADX415, which could potentially treat high blood pressure and other conditions.
Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension (Business Wire)
Date: Tue, 1 Jul 2008 12:30:00 Etc/GMT
Tags:
ATLANTA----Sciele Pharma, Inc. today announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals, Inc. to develop and market ADX415, a novel patented, centrally-acting alpha adrenergic receptor agonist, specific to Alpha-2 receptors, for the treatment of hypertension and other potential indications.
FDA approves Sciele's PrandiMet (at bizjournals.com)
Date: Tue, 24 Jun 2008 14:35:06 Etc/GMT
Tags:
FDA Approves PrandiMet(TM), a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes (Business Wire)
Date: Tue, 24 Jun 2008 13:57:00 Etc/GMT
Tags:
ATLANTA & PRINCETON, N.J.----Sciele Pharma, Inc. and Novo Nordisk Inc. today announced that the U.S. Food and Drug Administration approved PrandiMet⢠tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide and insulin sensitizer, metformin, for the treatment of type 2 diabetes.